Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.
cervical intraepithelial neoplasia
disease surveillance
human papillomavirus
vaccine impact
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 04 2019
08 04 2019
Historique:
received:
26
04
2018
accepted:
21
08
2018
pubmed:
24
8
2018
medline:
26
6
2020
entrez:
24
8
2018
Statut:
ppublish
Résumé
We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervical cancer screening recommendations. We conducted population-based laboratory surveillance for CIN2+ in catchment areas in 5 states, 2008-2015. We calculated age-specific CIN2+ rates per 100000 women by age groups. We estimated incidence rate ratios (IRR) of CIN2+ for 2-year periods among all women and among screened women to evaluate changes over time. A total of 16572 CIN2+ cases were reported. Among women aged 18-20 and 21-24 years, CIN2+ rates declined in all sites, whereas in women aged 25-29, 30-34, and 35-39 years, trends differed across sites. The percent of women screened annually declined in all sites and age groups. Compared to 2008-2009, rates among screened women were significantly lower for all 3 periods in women aged 18-20 years (2010-2011: IRR 0.82, 95% confidence interval [CI] 0.67-0.99; 2012-2013: IRR 0.63, 95% CI 0.47-0.85; 2014-2015: IRR 0.44, 95% CI 0.28-0.68) and lower for the latter 2 time periods in women aged 21-24 years (2012-2013: IRR 0.86, 95% CI 0.79-0.94; 2014-2015: IRR 0.61, 95% CI 0.55-0.67). From 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 years. The significant decreases in CIN2+ rates among screened women aged 18-24 years are consistent with a population-level impact of HPV vaccination.
Sections du résumé
BACKGROUND
We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervical cancer screening recommendations.
METHODS
We conducted population-based laboratory surveillance for CIN2+ in catchment areas in 5 states, 2008-2015. We calculated age-specific CIN2+ rates per 100000 women by age groups. We estimated incidence rate ratios (IRR) of CIN2+ for 2-year periods among all women and among screened women to evaluate changes over time.
RESULTS
A total of 16572 CIN2+ cases were reported. Among women aged 18-20 and 21-24 years, CIN2+ rates declined in all sites, whereas in women aged 25-29, 30-34, and 35-39 years, trends differed across sites. The percent of women screened annually declined in all sites and age groups. Compared to 2008-2009, rates among screened women were significantly lower for all 3 periods in women aged 18-20 years (2010-2011: IRR 0.82, 95% confidence interval [CI] 0.67-0.99; 2012-2013: IRR 0.63, 95% CI 0.47-0.85; 2014-2015: IRR 0.44, 95% CI 0.28-0.68) and lower for the latter 2 time periods in women aged 21-24 years (2012-2013: IRR 0.86, 95% CI 0.79-0.94; 2014-2015: IRR 0.61, 95% CI 0.55-0.67).
CONCLUSIONS
From 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 years. The significant decreases in CIN2+ rates among screened women aged 18-24 years are consistent with a population-level impact of HPV vaccination.
Identifiants
pubmed: 30137283
pii: 5078164
doi: 10.1093/cid/ciy707
pmc: PMC6783904
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1282-1291Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000042
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002001
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000482
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2018.
Références
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
Prev Med. 2017 Oct;103:60-65
pubmed: 28765084
MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4
pubmed: 25055185
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
J Low Genit Tract Dis. 2015 Apr;19(2):91-6
pubmed: 25574659
Cancer. 2015 Aug 15;121(16):2775-81
pubmed: 26098295
Am J Obstet Gynecol. 2003 Jun;188(6):1393-400
pubmed: 12824968
Am J Public Health. 2012 May;102(5):833-5
pubmed: 22420808
Am J Public Health. 2016 Dec;106(12):2211-2218
pubmed: 27736208
Med Clin North Am. 2017 Jul;101(4):743-753
pubmed: 28577624
Am J Public Health. 2013 Aug;103(8):1428-35
pubmed: 23763409
Obstet Gynecol. 2009 Dec;114(6):1409-20
pubmed: 20134296
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27
pubmed: 23519301
J Infect Dis. 2015 Dec 15;212(12):1970-5
pubmed: 26123561
Pediatrics. 2016 Mar;137(3):e20151968
pubmed: 26908697
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312
pubmed: 22711081
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):850-8
pubmed: 27561081
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
Lancet. 2011 Jun 18;377(9783):2085-92
pubmed: 21684381
Cancer Causes Control. 2014 Jul;25(7):915-22
pubmed: 24797870
J Infect Dis. 2017 Sep 1;216(5):594-603
pubmed: 28931217
J Infect Dis. 2013 Aug 1;208(3):385-93
pubmed: 23785124
Med J Aust. 2016 Mar 21;204(5):184-184e1
pubmed: 26985843
MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882
pubmed: 28837546
Emerg Infect Dis. 2015 Sep;21(9):1557-61
pubmed: 26291379
Int J Cancer. 2015 Oct 15;137(8):1931-7
pubmed: 25754686
J Adolesc Health. 2015 Apr;56(4):408-13
pubmed: 25797632
JAMA Oncol. 2017 Jun 1;3(6):833-837
pubmed: 27685805